# A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of Gastrodin Injection in Healthy Chinese Subjects

> **NCT07422142** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Kunming Pharmaceuticals, Inc.** · enrollment: 54 (estimated)

## Conditions studied

- Delirium

## Interventions

- **DRUG:** gastrodin injection；placebo
- **DRUG:** gastrodin injection；placebo

## Key facts

- **NCT ID:** NCT07422142
- **Lead sponsor:** Kunming Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03-01
- **Primary completion:** 2026-09-30
- **Final completion:** 2026-09-30
- **Target enrollment:** 54 (ESTIMATED)
- **Last updated:** 2026-02-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07422142

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07422142, "A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of Gastrodin Injection in Healthy Chinese Subjects". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT07422142. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*